In April 2020 the U.S. Food and Drug Administration (FDA) approved KOSELUGOTM (selumetinib) for use in children over age 2 with neurofibromatosis type 1 who have inoperable plexiform neurofibromas. This is the first drug ever approved specifically for a complication of NF Type 1. Obviously this has been huge news! The process of getting this…
Read MoreUpcoming Events
- Conversaciones constructivas con los profesionales sanitarios (Español)/Productive Conversations with Healthcare ProvidersNovember 5, 2026
- NF Parent ConversationsNovember 9, 2026
- Common Medical Terms on the Patient Journey (English)November 10, 2026
- Términos médicos habituales en el proceso asistencial del paciente (Español)/Common Medical Terms on the Patient Journey November 11, 2026
- NF1 Peer ConversationsNovember 24, 2026
- NF Parent ConversationsDecember 14, 2026